Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6016
- Development stage
- Unknown
- Lead developer
- CSPC Megalith Biopharmaceutical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
SYS6016 is an mRNA-based vaccine developed by CSPC Megalith Biopharmaceutical, a subsidiary of CSPC Pharmaceutical Group, for the prevention of lower respiratory tract diseases caused by Respiratory Syncytial Virus (RSV). The vaccine utilizes synthetic messenger RNA technology formulated in lipid nanoparticles (LNP) to target both RSV-A and RSV-B subtypes. By inducing the production of viral antigens, it triggers a protective antibody response. In July 2024, the Chinese National Medical Products Administration (NMPA) granted clinical trial approval for SYS6016 to enter Phase 1 human trials, following preclinical studies that demonstrated a favorable safety profile and long-lasting immunogenicity.
- Other names
- SYS6016SYS-6016SYS 6016
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on SYS6016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6016.